Cytek (CTKB) CTO Yan Ming Receives 33,270 Shares via RSU Vesting

What Happened

• Yan Ming, Chief Technology Officer and director of Cytek Biosciences (CTKB), had multiple Restricted Stock Units (RSUs) vest and convert into a total of 33,270 shares on August 18, 2026. To satisfy tax withholding obligations, the company withheld 8,088 of those shares at an effective withholding value of $4.67 per share (total ≈ $37,771). The net number of shares delivered to Yan Ming was approximately 25,182.
• These entries are recorded as derivative exercises/conversions (transaction code M) for the RSU vesting and as tax withholding (code F) for the surrendered shares. This is receipt of compensation (award vesting), not an open-market purchase or sale.

Key Details

• Transaction date: August 18, 2026; Form 4 filed August 20, 2026 (filed within the normal 2-business-day window).
• Shares: 33,270 shares converted from RSUs; 8,088 shares withheld for taxes at $4.67/share (total withheld ≈ $37,771); net ~25,182 shares delivered.
• Transaction codes: M = exercise/conversion of derivative (RSU conversion); F = payment of exercise price / tax withholding.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1–F6 indicate these were RSU awards (1 share per RSU) with multi-year vesting schedules and that the withheld shares were surrendered to satisfy tax obligations.

Context

• This is a routine compensation event: RSUs vesting and being converted to shares, with a portion withheld for taxes (a common net-settlement or share-withholding arrangement). Because holdings were acquired via vesting—and part withheld for taxes—this does not represent an open-market buy or sale that would signal a positive or negative trading view by the insider.